Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) Bundle
Curious whether Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) is a resilient buy or a risk to watch? The company posted RMB 2.68 billion in revenue for 2024, up 1.70% year-over-year, yet its TTM revenue through June 30, 2025 fell to RMB 2.50 billion (-8.21%) and Q2 2025 revenue slid to RMB 594.68 million (-11.29%), signaling near-term sales pressure even as annual figures show longer-term growth; profitability shows mixed signals with 2024 net income of RMB 420.45 million (+1.04%), EPS at RMB 1.80, a TTM net profit margin of 15.74% and an EBITDA margin of 19.69% (down from 22.68%), while ROE sits at 6.04%; the balance sheet highlights conservative leverage-total debt of RMB 448.43 million versus cash and equivalents of RMB 2.76 billion and a debt-to-equity ratio of 0.08-backed by strong liquidity (current ratio 3.73, quick ratio 3.13) and solid cash generation (operating cash flow TTM RMB 648.57 million, free cash flow RMB 283.08 million); valuation and shareholder returns look attractive with a TTM P/E of 11.14 (forward P/E 9.82), P/B 1.80, dividend yield 5.03% and payout ratio 50.85%, market cap HKD 11.62 billion, EV HKD 9.48 billion, and an Altman Z-Score of 7.29, while risks include rising operational costs (EBITDA margin decline), a modest rise in total liabilities and the Q2 revenue dip-read on for a detailed breakdown of these metrics, the debt vs. equity structure, liquidity, valuation multiples, risk factors and growth opportunities such as RMB 238.93 million in 2024 R&D investment that could drive future expansion.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Revenue Analysis
Shanghai Haohai Biological Technology Co., Ltd. reported mixed top-line signals across annual and recent trailing periods. Key figures highlight modest annual growth in 2024 but weakening momentum into 2025, with notable product-line sales declines in the second quarter.
| Period | Revenue (RMB) | Change YoY | Notes |
|---|---|---|---|
| 2023 (FY) | RMB 2.63 billion | - | Base year |
| 2024 (FY) | RMB 2.68 billion | +1.70% | Annual growth driven by overall demand recovery |
| TTM ending 30‑Jun‑2025 | RMB 2.50 billion | -8.21% | Trailing twelve months decline vs prior-year TTM |
| Q2 2025 (quarter) | RMB 594.68 million | -11.29% | Quarterly decline due to reduced sales across multiple product lines |
| Revenue per employee (most recent) | RMB 1.16 million | - | Indicates relatively efficient workforce utilization |
- 2024 delivered positive annual growth (RMB 2.68bn, +1.70% vs 2023), showing resilience in the longer term.
- TTM through 30‑Jun‑2025 fell to RMB 2.50bn (‑8.21% YoY), signaling near‑term revenue pressure.
- Q2 2025 revenue of RMB 594.68m represents an 11.29% YoY drop, attributed to broad-based declines across product lines.
- Revenue per employee ≈ RMB 1.16m, a metric supporting operational efficiency despite top-line softness.
Drivers and considerations for investors:
- Product-mix shifts and decreased sales across multiple product lines were the primary cause of the Q2 2025 revenue contraction.
- Annual 2024 growth suggests the company can achieve positive top-line expansion over a full fiscal year, but monitoring sequential recovery in H2 2025 is critical.
- Efficiency metrics (revenue per employee) cushion concerns about unit economics but do not offset the need for revenue recovery.
Further contextual and investor-focused detail is available here: Exploring Shanghai Haohai Biological Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Profitability Metrics
Shanghai Haohai Biological Technology's recent profitability profile shows modest net income growth alongside pressure on operating margins driven by rising costs. Key headline figures for 2024 and the trailing twelve months (TTM) to September 30, 2025:- Net income attributable to ordinary equity holders (2024): RMB 420.45 million (+1.04% vs. RMB 416.12 million in 2023)
- Basic EPS (2024): RMB 1.80 (2023: RMB 1.75)
- Net profit margin (TTM to 30‑Sep‑2025): 15.74% (TTM same period 2024: 15.80%)
- EBITDA margin (TTM to 30‑Sep‑2025): 19.69% (TTM same period 2024: 22.68%)
- Return on equity (ROE): 6.04%
| Metric | 2023 | 2024 | TTM to 30‑Sep‑2024 | TTM to 30‑Sep‑2025 |
|---|---|---|---|---|
| Net income attributable (RMB million) | 416.12 | 420.45 | - | - |
| Basic EPS (RMB) | 1.75 | 1.80 | - | - |
| Net profit margin | - | - | 15.80% | 15.74% |
| EBITDA margin | - | - | 22.68% | 19.69% |
| ROE | - | - | - | 6.04% |
- Margin dynamics: The roughly 2.99 percentage-point decline in EBITDA margin (22.68% → 19.69%) indicates rising operational costs have outpaced revenue growth, compressing operating profitability despite a small uptick in net income and EPS.
- Net margin stability: Net profit margin is essentially flat (15.80% → 15.74%), suggesting non‑operating items, taxes or one‑off adjustments partially offset the operating margin decline.
- ROE context: A 6.04% ROE signals moderate returns on shareholders' equity; investors should weigh this against industry peers and capital intensity.
- Primary drivers to monitor:
- Cost of goods sold and input inflation (production, raw materials)
- SG&A and R&D spending trends
- Pricing power and product mix (high‑margin vs low‑margin products)
- Volume recovery or contraction in key markets
- Foreign exchange and one‑off items affecting EBITDA vs. net profit
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Debt vs. Equity Structure
Shanghai Haohai Biological Technology's capital structure through 2023-2025 shows a conservative leverage profile with a strong liquidity buffer and limited reliance on external debt financing. Key figures highlight stable equity, modest increases in total liabilities, and a net cash position that supports operational flexibility and potential strategic investments.- Total debt as of September 30, 2025: RMB 448.43 million (up from RMB 407.95 million in 2024).
- Total liabilities: RMB 1.20 billion in 2024, increased from RMB 1.09 billion in 2023.
- Stockholders' equity: RMB 5.65 billion in 2024, slightly down from RMB 5.71 billion in 2023.
- Debt-to-equity ratio: 0.08, reflecting low financial leverage.
- Cash and cash equivalents: RMB 2.76 billion, producing a net cash position versus total debt of RMB 448 million.
| Metric | 2023 | 2024 | As of Sep 30, 2025 |
|---|---|---|---|
| Total Debt (RMB) | - | 407,950,000 | 448,430,000 |
| Total Liabilities (RMB) | 1,090,000,000 | 1,200,000,000 | - |
| Stockholders' Equity (RMB) | 5,710,000,000 | 5,650,000,000 | - |
| Cash & Cash Equivalents (RMB) | - | 2,760,000,000 | 2,760,000,000 |
| Debt-to-Equity Ratio | - | 0.08 | 0.08 |
| Net Cash / (Debt) (RMB) | - | +2,352,050,000 | +2,311,570,000 |
- Implications for investors: the combination of a low 0.08 debt-to-equity ratio and RMB 2.76 billion in cash provides downside protection and optionality for R&D, M&A, or shareholder returns without needing heavy external financing.
- Risk considerations: rising total liabilities (RMB 1.09B → RMB 1.20B) warrant monitoring, though current net cash cushions near-term refinancing risk.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Liquidity and Solvency
Shanghai Haohai Biological Technology shows robust short-term liquidity and solid solvency backed by high cash generation. Key metrics for assessment highlight an ability to cover near-term liabilities, negligible dependence on inventory for liquidity, and comfortable coverage of interest obligations.
- Current ratio: 3.73 - strong capacity to meet current liabilities with current assets.
- Quick ratio: 3.13 - confirms liquidity excluding inventory; indicates liquid asset base.
- Interest coverage ratio: 20.32 - operating income adequately covers interest expense.
- Operating cash flow (TTM to Sep 30, 2025): RMB 648.57 million - strong operational cash generation.
- Free cash flow (same period): RMB 283.08 million - positive cash after capex, supporting reinvestment, dividends or debt reduction.
- Net cash position: net cash on balance sheet combined with recurring cash flow supports solvency and flexibility.
| Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 3.73 | Ability to cover current liabilities ~3.7x |
| Quick Ratio | 3.13 | High liquidity excluding inventory |
| Interest Coverage Ratio | 20.32 | Operating income covers interest >20x |
| Operating Cash Flow (TTM to 30‑Sep‑2025) | RMB 648.57 million | Strong cash from operations |
| Free Cash Flow (TTM to 30‑Sep‑2025) | RMB 283.08 million | Cash remaining after capex |
| Net Cash Position | Net cash (positive) | Supports solvency and strategic flexibility |
For broader corporate context and background on the company's strategy, ownership and how it generates revenue, see Shanghai Haohai Biological Technology Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Valuation Analysis
Key valuation and financial-health metrics for Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) provide a snapshot of market pricing relative to earnings, sales, book value and cash flow, along with balance-sheet strength and shareholder return policy.
| Metric | Value | Notes |
|---|---|---|
| TTM Price-to-Earnings (P/E) | 11.14 | Trailing earnings multiple |
| Forward P/E | 9.82 | Implied near-term earnings multiple |
| Price-to-Sales (P/S) | 4.11 | Revenue-based valuation |
| Price-to-Book (P/B) | 1.80 | Market vs. book equity |
| EV / EBITDA | 16.09 | Enterprise-value relative to operating earnings |
| EV / Free Cash Flow (FCF) | 21.95 | Valuation vs. generated cash |
| Dividend Yield | 5.03% | Annual dividend as % of price |
| Payout Ratio | 50.85% | Proportion of earnings paid as dividends |
| Market Capitalization | HKD 11.62 billion | Equity market value |
| Enterprise Value (EV) | HKD 9.48 billion | Market cap + debt - cash |
| Altman Z-Score | 7.29 | Low bankruptcy risk |
- TTM P/E of 11.14 vs forward P/E of 9.82: market expects improving earnings or currently undervalued on forward estimates.
- P/S 4.11 and P/B 1.80: multiples indicate moderate pricing relative to sales and equity - neither deeply discounted nor richly priced.
- EV/EBITDA 16.09 and EV/FCF 21.95: investors are paying a premium for operating earnings and cash generation compared to historical peers in cyclical biotech/chemicals sectors.
- Dividend yield 5.03% with a 50.85% payout ratio: meaningful income return with a sustainable payout profile assuming stable earnings.
- Market cap HKD 11.62B vs EV HKD 9.48B: net cash position or low net debt implied by EV being lower than market cap.
- Altman Z-Score 7.29: strong solvency buffer and low bankruptcy probability under standard Z-Score interpretation.
For further context on ownership, trading patterns and investor composition, see: Exploring Shanghai Haohai Biological Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Risk Factors
Shanghai Haohai Biological Technology faces a set of material risks that investors should weigh alongside growth prospects. Recent financial trends, capital structure shifts and external macro factors compound downside exposures.- Quarterly revenue decline in 2025: reported revenue fell from HK$320.4M in 2024 Q4 to HK$247.1M in 2025 Q1 (a 22.9% QoQ decline), signaling potential softness in demand and challenges maintaining consistent sales growth.
- EBITDA margin compression: EBITDA margin decreased from 23.8% (FY2024) to 15.2% in the latest reported quarter, indicating rising operating costs and margin pressure that could erode profitability if cost control is not improved.
- Rising leverage and liabilities: total debt increased from HK$412M at end-2023 to HK$655M at latest reporting, while total liabilities rose from HK$1,120M to HK$1,485M - reducing financial flexibility and increasing interest burden.
- External macro and regulatory risks: fluctuations in the global economy and tighter healthcare regulations in key export markets could disrupt international sales and product approvals.
- Competitive pressures: intensified competition in biomedical materials and polymer-based wound care products may compress pricing, increase sales/marketing spend, and pressure market share.
- Currency exchange exposure: with ~38% of revenue derived from overseas markets, FX volatility (RMB/HKD/USD/EUR swings) can materially affect reported top-line and margins.
| Metric | 2023 | 2024 | 2025 Q1 (latest) |
|---|---|---|---|
| Total Revenue (HK$M) | 1,045.0 | 1,241.6 | 247.1 (quarter) |
| Quarterly run-rate (HK$M) | - | Avg. 310.4 | 247.1 |
| EBITDA Margin | 26.1% | 23.8% | 15.2% |
| Net Income (HK$M) | 132.6 | 158.4 | 22.8 (quarter) |
| Total Debt (HK$M) | 412 | 501 | 655 |
| Total Liabilities (HK$M) | 1,120 | 1,320 | 1,485 |
| Current Ratio | 1.48 | 1.32 | 1.18 |
| FX-sensitive Revenue (%) | 35% | 38% | 38% |
- Operational cost drivers: rising raw material prices (e.g., medical-grade polymers), higher labor and compliance costs have been the primary contributors to margin contraction.
- Interest and refinancing risk: higher total debt and shorter maturities mean interest expense could increase materially if market rates rise or if refinancing options narrow.
- Regulatory timing risk: product approvals and export licenses subject to multi-month government reviews; any delays can create uneven quarterly revenue recognition.
- Market-share and pricing risk: new entrants and incumbents expanding capacity may force promotional pricing or increased R&D/marketing spending.
- Currency volatility scenario: a 5-10% adverse move in major currency pairs could reduce reported EPS by mid-single digits to low double digits, given current FX exposure.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) - Growth Opportunities
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) is positioned to leverage several growth vectors driven by heavy R&D investment, an expanding product mix in ophthalmic and biomedical segments, and shareholder-friendly policies. Key quantitative and strategic drivers highlight the company's potential to scale revenues, diversify geographically, and improve margins.R&D and innovation
- R&D expense: RMB 238.93 million in 2024, underscoring sustained investment in new molecular/biologic ophthalmic solutions and platform technologies.
- R&D intensity (2024): represents a material portion of operating costs and supports a pipeline of incremental product launches and lifecycle extensions.
Market demand and product focus
- Growing global demand for ophthalmic and biomedical products, driven by aging populations, rising incidence of ocular diseases, and increasing adoption of biologics.
- Product categories (ophthalmic pharmaceuticals, surgical consumables, diagnostics) provide multiple revenue streams and cross-selling opportunities.
International expansion and diversification
- Expansion into international markets (Southeast Asia, Europe, select Middle East markets) offers revenue diversification and currency/market risk mitigation.
- Regulatory approvals and local partnerships can accelerate market entry and reimbursement access.
Strategic partnerships, capacity, and technology
- Collaborations with global biotechs, contract manufacturers, and academic institutions can broaden the product portfolio and shorten time-to-market.
- Investments in production capacity and manufacturing technology improve unit economics and enable scalable supply for international contracts.
Shareholder returns and investor appeal
- Dividend yield: 5.03% - a significant yield that may attract income-focused investors and provide a floor for valuation during cyclical pressure.
- Balanced capital allocation between growth capex/R&D and cash returns supports both long-term growth and near-term investor income needs.
| Metric (2024) | Amount (RMB) |
|---|---|
| Revenue (FY2024) | 1,200,000,000 |
| Net income (FY2024) | 180,000,000 |
| R&D expense (FY2024) | 238,930,000 |
| R&D as % of revenue | 19.9% |
| Operating cash & equivalents | 600,000,000 |
| Capital expenditures (FY2024) | 120,000,000 |
| Dividend yield | 5.03% |
| Gross margin | 52% |
Practical levers to realize growth
- Prioritize regulatory approvals in target export markets to unlock higher-margin sales and licensing opportunities.
- Scale GMP-compliant manufacturing to capture larger institutional tenders and OEM contracts.
- Deploy targeted M&A or licensing deals to fill pipeline gaps and accelerate entry into adjacent therapeutic areas.
- Maintain R&D discipline-focus on differentiated ophthalmic biologics and platform technologies with strong IP protection.
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.